학술논문
Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK‐Positive Non‐small Cell Lung Cancer
Document Type
Article
Author
Source
In Clinical Lung Cancer April 2024
Subject
Language
ISSN
1525-7304